Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 45,563 | 14,090 | 102,694 | 0 | 0 |
| Gross Profit | 45,563 | 14,090 | 102,694 | N/A | N/A |
| Operating Expenses | 221,852 | 197,057 | 106,251 | 1,366 | 128 |
| Operating Income | -176,289 | -182,967 | -3,557 | -1,366 | -128 |
| Interest Expense | 0 | 0 | 287 | 0 | 0 |
| Other Income | -65,310 | 6,057 | -18,790 | 5,545 | 169 |
| Pre-tax Income | -241,599 | -176,910 | -22,634 | 4,179 | 42 |
| Income Tax | -1 | 27 | N/A | N/A | N/A |
| Net Income Continuous | -241,598 | -176,937 | -22,634 | 4,179 | 42 |
| Net Income | $-241,598 | $-176,937 | $-22,634 | $4,179 | $42 |
| EPS Basic Total Ops | -2.56 | -2.15 | -1.19 | 0.24 | 0.01 |
| EPS Basic Continuous Ops | -2.56 | -2.15 | -1.19 | 1.21 | 0.01 |
| EPS Diluted Total Ops | -2.56 | -2.15 | -1.19 | 0.24 | 0.01 |
| EPS Diluted Continuous Ops | -2.56 | -2.15 | -1.19 | 1.21 | 0.01 |
| EPS Diluted Before Non-Recurring Items | -2.22 | -2.15 | -1.01 | N/A | N/A |
| EBITDA(a) | $-176,176 | $-182,918 | $-3,548 | $-1,366 | $-128 |